Can Lithium 900 mg TID Be Changed to BID?
Yes, lithium 900 mg three times daily can be safely changed to twice daily dosing, and this change may actually reduce side effects—particularly urinary frequency—while maintaining equivalent therapeutic efficacy. The total daily dose of 2700 mg would be split into 1350 mg twice daily, maintaining the same therapeutic serum levels.
Evidence Supporting BID Dosing
The FDA-approved labeling for lithium explicitly supports both TID and QID dosing schedules 1. More importantly, extensive research demonstrates that once-daily and twice-daily regimens are equally effective as three-times-daily dosing for maintaining therapeutic serum lithium levels and preventing mood episodes 2, 3, 4.
Key Advantages of BID Over TID
Reduced renal side effects represent the most clinically significant benefit of less frequent dosing:
- Patients receiving twice-daily lithium experience significantly lower urinary frequency compared to those on more frequent dosing schedules 5
- The once-daily regimen has been shown to prevent or limit increases in urine output and subsequent thirst 3
- A positive correlation exists between urinary frequency and total daily lithium dose when split into multiple administrations 5
Improved medication adherence is another practical advantage, as compliance with midday doses is often questionable 2.
Pharmacokinetic Considerations
While less frequent dosing creates higher peak plasma concentrations, this does not translate to increased toxicity or reduced efficacy:
- Brain lithium concentrations closely mirror serum profiles but equilibrate at the standard 12-hour post-dose sampling timepoint regardless of dosing regimen 6
- No comparative studies have revealed significant differences in side effects between multiple and single daily dosing groups 3
- The therapeutic range of 0.6-1.2 mEq/L is maintained with both regimens when properly monitored 1
Implementation Protocol
To convert from TID to BID dosing:
- Calculate the total daily dose: 900 mg × 3 = 2700 mg/day
- Split into two equal doses: 1350 mg twice daily (morning and evening)
- Monitor serum lithium levels 5-7 days after the change, drawn 12 hours post-dose
- Assess for side effects, particularly GI distress from higher individual doses
- Adjust timing if needed—evening-weighted dosing (e.g., 900 mg AM, 1800 mg PM) may further reduce polyuria
Monitoring Requirements
After converting to BID dosing 1:
- Check serum lithium levels within one week of the change
- Ensure levels remain in the therapeutic range of 0.6-1.2 mEq/L
- Monitor renal function (serum creatinine) given lithium's nephrotoxic potential 7, 8
- Assess for urinary symptoms—patients should report any changes in frequency or volume
- Continue routine monitoring every 2 months once stable 1
Important Caveats
Elderly patients may require dose reduction regardless of frequency, as they often exhibit toxicity at levels tolerated by younger patients 9, 1. Blood levels of 0.2-0.6 mEq/L are generally adequate in this population 9.
Renal impairment is a critical consideration—lithium is contraindicated in significant renal disease 1. If GFR is compromised, dosing frequency should be reduced further (to 2-3 times weekly, not daily) while maintaining the per-dose amount at 12-15 mg/kg to preserve concentration-dependent efficacy 10, 7.
Drug interactions that reduce lithium clearance (NSAIDs, ACE inhibitors, thiazide diuretics) require heightened vigilance regardless of dosing frequency 7, 11.
The conversion from TID to BID dosing represents an evidence-based optimization that maintains efficacy while potentially improving tolerability and adherence.